Patents Assigned to Onyx Therapeutics, Inc.
-
Publication number: 20230235406Abstract: Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.Type: ApplicationFiled: September 6, 2022Publication date: July 27, 2023Applicant: Onyx Therapeutics, Inc.Inventors: Brian TUCH, Jeremiah DEGENHARDT, Andrea LOEHR, Kevin KWEI, Christopher J. KIRK
-
Patent number: 11078233Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.Type: GrantFiled: March 13, 2020Date of Patent: August 3, 2021Assignee: Onyx Therapeutics, Inc.Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
-
Patent number: 10870889Abstract: Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.Type: GrantFiled: August 8, 2014Date of Patent: December 22, 2020Assignee: Onyx Therapeutics, Inc.Inventors: Brian Tuch, Jeremiah Degenhardt, Andrea Loehr, Kevin Kwei, Christopher J. Kirk
-
Patent number: 10682419Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.Type: GrantFiled: January 29, 2018Date of Patent: June 16, 2020Assignee: ONYX THERAPEUTICS, INC.Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
-
Patent number: 10662479Abstract: Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.Type: GrantFiled: August 8, 2014Date of Patent: May 26, 2020Assignee: Onyx Therapeutics, Inc.Inventors: Brian Tuch, Jeremiah Degenhardt, Andrea Loehr, Kevin Kwei, Christopher J. Kirk
-
Patent number: 10647744Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.Type: GrantFiled: August 30, 2016Date of Patent: May 12, 2020Assignee: Onyx Therapeutics, Inc.Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
-
Patent number: 10596222Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.Type: GrantFiled: November 2, 2016Date of Patent: March 24, 2020Assignee: ONYX THERAPEUTICS, INC.Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
-
Patent number: 10159746Abstract: This disclosure provides methods for formulating compositions comprising one or more peptide proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin. As well as cyclodextrin complexation methods of formulating a peptide proteasome inhibitor (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof) with one or more cyclodextrins. Such methods substantially increase the solubility and stability of these proteasome inhibitors and facilitate both their manufacture and administration. For example, homogenous solutions of a compound of formula (5) (carfilzomib) can be obtained at a pharmaceutically useful pH (e.g., about 3.5) and at higher concentrations (e.g., about 5 mg/mL) than could be obtained without one or more cyclodextrins and the processes of complexation between the compound and one or more cyclodextrins provided herein.Type: GrantFiled: May 8, 2013Date of Patent: December 25, 2018Assignee: Onyx Therapeutics, Inc.Inventors: Evan Lewis, Peter Shwonek, Sean Dalziel, Mouhannad Jumaa
-
Patent number: 10150794Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.Type: GrantFiled: May 26, 2017Date of Patent: December 11, 2018Assignee: Onyx Therapeutics, Inc.Inventors: Han-Jie Zhou, Congcong M. Sun, Kevin D. Shenk, Guy J. Laidig
-
Patent number: 10022326Abstract: Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions enhance the therapeutic window of peptide epoxyketone compounds by improving in vivo half-life relative to non-liposomal compositions comprising peptide epoxyketone compounds, providing desirable pharmacodynamic profiles, and providing anti-tumor activity in a human tumor xenograft model, greater than or equal to non-liposomal compositions comprising peptide epoxyketone compounds. Further, experiments performed in support of the present invention demonstrated improved tolerability of liposomal compositions comprising peptide epoxyketone compounds.Type: GrantFiled: July 17, 2013Date of Patent: July 17, 2018Assignee: Onyx Therapeutics, Inc.Inventors: Katherine A. Chu, Elena T. Chan, Ying Fang, Mouhannad Jamaa, Christopher Justin Kirk, Tony Muchamuel, Zhengping Wang, Jing Jiang, Jeffrey Joseph Jones
-
Patent number: 9878047Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.Type: GrantFiled: March 9, 2016Date of Patent: January 30, 2018Assignee: Onyx Therapeutics, Inc.Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
-
Patent number: 9657058Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: GrantFiled: January 7, 2015Date of Patent: May 23, 2017Assignee: Onyx Therapeutics, Inc.Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
-
Patent number: 9657057Abstract: Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.Type: GrantFiled: March 14, 2014Date of Patent: May 23, 2017Assignee: Onyx Therapeutics, Inc.Inventors: Dustin McMinn, Henry Johnson, David C. Moebius
-
Patent number: 9511109Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.Type: GrantFiled: August 27, 2014Date of Patent: December 6, 2016Assignee: Onyx Therapeutics, Inc.Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
-
Patent number: 9434761Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.Type: GrantFiled: March 14, 2014Date of Patent: September 6, 2016Assignee: Onyx Therapeutics, Inc.Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
-
Patent number: 9403868Abstract: The invention relates to crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.Type: GrantFiled: March 5, 2015Date of Patent: August 2, 2016Assignee: Onyx Therapeutics, Inc.Inventors: Pasit Phiasivongsa, Louis C. Sehl
-
Patent number: 9359398Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: GrantFiled: March 1, 2011Date of Patent: June 7, 2016Assignee: Onyx Therapeutics, Inc.Inventors: Kevin D. Shenk, Francesco Parlati, Mark K. Bennett
-
Patent number: 9315542Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.Type: GrantFiled: September 30, 2013Date of Patent: April 19, 2016Assignee: Onyx Therapeutics, Inc.Inventors: Pasit Phiasivongsa, Gary Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
-
Patent number: RE47302Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.Type: GrantFiled: June 23, 2017Date of Patent: March 19, 2019Assignee: ONYX THERAPEUTICS INC.Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
-
Patent number: RE47954Abstract: ABSTRACT The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.Type: GrantFiled: June 30, 2017Date of Patent: April 21, 2020Assignee: Onyx Therapeutics, Inc.Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett